Argos Therapeutics Welcomes Jean Lamarre to Board of Directors
March 13, 2013 09:30 ET
|
Argos Therapeutics
DURHAM, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Validates Durability of AGS-003 Induced Immune Response in mRCC Patients
March 04, 2013 08:01 ET
|
Argos Therapeutics
DURHAM, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma
February 14, 2013 08:01 ET
|
Argos Therapeutics
DURHAM, N.C., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum
January 28, 2013 08:01 ET
|
Argos Therapeutics
DURHAM, N.C., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Study Confirms Optimal Quality Control Methods for Production of Its RNA-Based Immunotherapies
November 15, 2012 14:19 ET
|
Argos Therapeutics
DURHAM, N.C., Nov. 15, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Southeast BIO Recognizes Argos Therapeutics with the "2012 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
November 02, 2012 08:00 ET
|
Argos Therapeutics
DURHAM, N.C., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003
October 11, 2012 10:49 ET
|
Argos Therapeutics
DURHAM, N.C., Oct. 11, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics' Phase 3 ADAPT Study for AGS-003 Highlighted During 11th Annual International Kidney Cancer Symposium
October 08, 2012 08:04 ET
|
Argos Therapeutics
DURHAM, N.C., Oct. 8, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Invited to Present at Two Biotech Industry Conferences
September 27, 2012 08:01 ET
|
Argos Therapeutics
DURHAM, N.C., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics to Present at Noble Financial Capital Markets' BIOX Life Sciences Exposition
September 20, 2012 08:01 ET
|
Argos Therapeutics
DURHAM, N.C., Sept. 20, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...